Navigation Links
Neurocrine Biosciences Reports First Quarter 2012 Results
Date:5/2/2012

is study assessed once-daily NBI-98854 (12.5mg or 50mg) over a two-week dosing period in 37 randomized subjects. Based on the positive outcome of this study the Company is planning to launch a large Phase IIb trial in mid-2012. This placebo controlled, double-blind, parallel design, multiple dose, twelve week study will assess six-week dosing of NBI-98854, against placebo, followed by six weeks of active treatment with NBI-98854. The study will incorporate a capsule formulation of NBI-98854.

In January of 2012, the Company was notified that the FDA Division of Psychiatry Products had granted Fast Track status to NBI-98854 for neuroleptic-induced tardive dyskinesia. The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious diseases and address unmet medical needs.

Urocortin 2 Update
The Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is conducting a Phase II study of urocortin 2 in acute decompensated heart failure patients. This study is now complete and top-line results are expected shortly.

The Company has completed several Phase I studies and two Phase II studies of urocortin 2 in patients with stable congestive heart failure. These Phase II studies showed urocortin 2 to be well tolerated with positive hemodynamic effects as evidenced by increases in cardiac output and efficiency.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 800-894-5910 (US) or 785-424-1052 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com<
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DUBLIN , Sept. 29, 2014 Research ... "Cardiac Pacemakers - Global Trends, Estimates and Forecasts, 2012-2018" ... sector is projected to reach US$5.7 billion by 2016. The ... global market share while Europe claims ... fastest growing region with a CAGR of 11.4% driving a ...
(Date:9/29/2014)... 2014  Guerbet, a pioneer in the field ... a Drug Shortage Assistance Award from the U.S. ... preventing or alleviating a drug shortage. ... to the shortage of Ethiodol (ethiodized oil) injection, ... post-approval supplements to restart manufacturing with acceptable compliance ...
(Date:9/29/2014)... , Sept. 29, 2014 Adaptive ... Next Generation Sequencing to profile the adaptive immune ... Scientific Advisory Board to provide strategic and clinical ... suite of assays in the diagnosis and monitoring ... focus of the SAB will be to support ...
Breaking Medicine Technology:Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 2Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 3Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 4Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 5Guerbet Receives FDA's Drug Shortage Assistance Award: Recognized for contributions to address a shortage of Ethiodol (ethiodized oil) injection 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
(Date:9/29/2014)... retrospective study led by researchers at Brigham and ... colonoscopies for colorectal cancer screening and surveillance. The ... intervals than established guidelines support, and these recommendations ... , "Our study shows that a high percentage ... resulting in use of scarce health care resources ...
(Date:9/29/2014)... Atlantic NeuroSurgical Specialists (ANS) brain ... to celebrate their strides in their fight against brain cancer. ... at their Morristown office. , The annual BBQ has grown ... a place where patients can find love, hope and support ... and activities were enjoyed by guests, including a dunk tank ...
(Date:9/29/2014)... September 30, 2014 NAPW ... as a 2014 Professional Woman of the Year. Ms. ... in home healthcare. As the largest networking organization of ... and profession, the National Association of Professional Women is ... and nearly 300 Local Chapters. , “I love the ...
(Date:9/29/2014)... NY (PRWEB) September 30, 2014 ... B.S.N., Clinical Manager Specialist, as a 2014 Professional Woman ... prestigious distinction for leadership in clinical care. As the ... spanning virtually every industry and profession, the National Association ... with over 600,000 members and nearly 300 Local Chapters. ...
(Date:9/29/2014)... September 30, 2014 Top10BestSEOHosting.com is ... reviews about hosting products. It is headed by ... experience. The site offers research-based information and factual ... suppliers in the current market. , Top10BestSEOHosting.com ... announced that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ) and Bluehost ...
Breaking Medicine News(10 mins):Health News:Endoscopists recommend frequent colonoscopies, leading to its overuse 2Health News:Local Brain Tumor Foundation, ANS Center of Hope, Celebrates its Brain Cancer Patients 2Health News:National Association of Professional Women Announces Carol A. Stormer, Home Health Occupational at LHC GroupTherapist, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Sarah Shiermeister, Clinical Manager Specialist at Gentiva Health Services, a 2014 Professional Woman of the Year 2Health News:Top10BestSEOHosting.com: New Reviews for Linux Web Hosting Suppliers Available Online 2
... standard for grading, staging and "stad-ging" the chronic liver ... acquiring new knowledge on the liver pathology. Demand for ... in liver biopsy samples has been fuelled by the ... molecules on the lesions characterising the histological patterns of ...
... 31 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the ... leading China-based medical device,company that develops, manufactures ... that the Company has completed the previously,announced ... tumor therapy system,business (the "HIFU Business") to ...
... in Near Term Continue Trading Under the Ticker ... HAXS ) and BPO Management Services, Inc., ... focused on serving middle-market enterprises, today jointly announced ... the previously announced merger in which BPOMS will ...
... Dec. 30 Scantek Medical, Inc. (Pink ... it filed a voluntary petition in the United States ... of the United States Code. Scantek also announced ... BreastCare(TM)/BreastAlert(TM) Differential Temperature Sensor product ("BreastCare") to a medical ...
... CAMBRIDGE, Mass., Dec. 30 Biopure Corporation (Nasdaq: ... has advised the U.S. Naval Medical Research Center ("NMRC") by ... Biopure,s product Hemopure [hemoglobin glutamer - 250 (bovine)], under a ... As previously announced, the Navy had filed a protocol ...
... Dec. 30 Biopure Corporation (Nasdaq: BPUR ... The NASDAQ Stock Market stating that NASDAQ has again ... value requirements for continued listing, thereby extending the Company,s ... these rules is scheduled to resume on Monday, April ...
Cached Medicine News:Health News:A rigorous method for liver biopsy 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 3Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 4Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 5Health News:Healthaxis and BPO Management Services, Inc. Announce Closing of Merger 2Health News:Healthaxis and BPO Management Services, Inc. Announce Closing of Merger 3Health News:Scantek Medical Files for Chapter 11 Voluntary Bankruptcy and Receives Orders for the Sale of BreastCare(TM) 2Health News:U.S. Navy Requested Operations Trial on FDA Hold 2Health News:U.S. Navy Requested Operations Trial on FDA Hold 3Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2
... Catalyst system introduces a new ... to microsurgical instrumentation. It has ... design with advanced microcomputer control ... to operate with a full ...
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
... Horizon Phacoemulsification System is ... surgical system. Lightweight and ... performance and features in ... also provides all modes ...
Compact ultrasonic phacoemulsification system....
Medicine Products: